Can avatrombopag be taken long-term?

Avatrombopag (Avatrombopag, trade name: Sucoxin, is an oral thrombopoietin receptor agonist, mainly used to treat thrombocytopenia associated with chronic liver disease (CLD). It stimulates the proliferation and differentiation of megakaryocytes in the bone marrow and promotes the production of platelets, thereby effectively increasing the patient's platelet count and reducing the risk of bleeding. However, several aspects need to be considered regarding whether avatrombopag can be taken long-term.

Generally speaking, avatrombopag is not suitable for long-term use. According to the drug's instructions for use and clinical practice experience, the recommended treatment course of avatrombopag is usually taken orally for 5 consecutive days. This is because after taking it for 5 consecutive days, the platelet count of most patients will significantly increase, achieving the therapeutic purpose. In addition, long-term use of avatrombopag may increase the risk of thrombotic and thromboembolic complications, which may be higher in patients with known risk factors for thromboembolism.

Of course, in some special circumstances, such as when a patient's platelet count continues to be low and needs to be maintained at a certain level for a long time to prevent the risk of bleeding, doctors may adjust the treatment plan according to the patient's specific situation, including extending the use of avatrombopag. But this needs to be done under close medical supervision, and the patient's platelet count and coagulation function need to be regularly monitored to ensure the safety and effectiveness of the treatment.

It is worth noting that the use of avatrombopag should strictly follow medical instructions, and patients should not decide to extend or shorten the medication time at their own discretion. During the medication, if the patient experiences any uncomfortable symptoms or adverse reactions, he or she should seek medical attention immediately and inform the doctor of the status of using avatrombopag.

To sum up, long-term use of avatrombopag is usually not recommended. The medication time and dosage should be determined based on the patient's specific condition and the guidance of the doctor. During the medication period, the patient's platelet count, coagulation function and other indicators need to be closely monitored to ensure the safety and effectiveness of the treatment.